Can an Immune-Modulating drug clear Alzheimer's brain plaques?

NCT ID NCT06862960

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This phase 2 trial investigates whether ozanimod, an oral drug that regulates the immune system, can reduce brain amyloid plaques and inflammation in people with moderate Alzheimer's disease. Forty participants aged 55 to 80 will receive either ozanimod or standard Alzheimer's medications for 27 weeks. The study uses brain scans and blood tests to measure changes in amyloid burden and neuroinflammation, comparing the two groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ozanimod, an oral drug that modulates the immune system by targeting sphingosine-1-phosphate receptors
What this could lead to
If successful, this could point toward a new treatment approach for Alzheimer's disease that targets inflammation and amyloid buildup in the brain.
What could go wrong
This is an early proof-of-concept study with only 40 participants, so results may not apply broadly. Ozanimod is already approved for other conditions, but its effects on Alzheimer's are unknown, and side effects like heart rate changes or infections are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease Cognitive Dysfunction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fujian Medical University Union Hospital

    RECRUITING

    Fuzhou, Fujian, 350001, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.